Fate Therapeutics Q1 2026: $174.8M cash, $1.3M revenue; FT819 lupus trial on track

FATE THERAPEUTICS INC

2026-Q1 EPS reported -$0.26 revenue$1,299,000

Cash, equivalents, and investments of $174.8M as of March 31, 2026; operating runway extended into 2028.
Total revenue $1.3M from Ono Pharmaceutical collaboration; total operating expenses $34.3M (R&D $24.7M, G&A $9.6M, including $3.9M stock-based comp).
RECLAIM-LN Phase 2 potentially registrational trial of FT819 for lupus nephritis on track to initiate in H2 2026; approximately 53 patients planned.
FT819 selected into FDA CDRP program for enhanced CMC engagement; also has RMAT designation for SLE.
FT839 IND planned H2 2026 for autoimmune diseases; FT836 Phase 1 enrolling solid tumor patients with no ICANS/GvHD/CRS or DLTs observed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

FATE THERAPEUTICS INC reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 13, 2026, Fate Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

571 earnings releases filed in the last 30 days. Browse all earnings releases →

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-220691

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.